Astrazeneca Stock Earnings Reports

AstraZeneca reported a strong start to 2026 with Q1 revenue up 8% (product revenue +8%), core operating profit up 12% and core EPS up 5%. Management reiterated full-year guidance: total revenue growth of mid- to high single digits and core EPS growth of low double digits at constant exchange rates. Performance was broad-based: Oncology (+16% total revenues in the business) and Rare Disease (+15%) delivered double-digit growth; Biopharmaceuticals were broadly stable with some headwinds from LOE and pricing (CVRM -6%). The company highlighted multiple recent and upcoming R&D and regulatory catalysts: four positive Phase III readouts already in 2026 (notably tozorakimab in COPD and efzimfotase alfa in HPP), continued pipeline progression (including ADCs, bispecifics, CAR-T), and an eventful 2026 with a potential wave of approvals (potentially 4 NMEs). Key commercial catalysts include an expected PDUFA for baxdrostat in Q2 2026, ongoing rollouts for Enhertu in earlier breast cancer settings, and expansion of indications for immuno-oncology agents (Imfinzi/Imjudo). AstraZeneca is increasing R&D investment (core R&D +8% in Q1; active trials +10%, enrolled patients +30% YoY) and CapEx (planned +~33% in 2026) to support launches and transformative technologies (cell therapies, T-cell engagers). Cash flow remained strong (operating cash flow $3.4bn), although net debt rose modestly (driven by dividend payment and deal-related outflows); milestone payments of ~ $2.5bn are expected for the year. Management emphasized a multi-year growth outlook toward their 2030 ambition driven by a broad portfolio, pipeline, and commercial investments.